Cue Biopharma, Inc.

DB:1UC Stock Report

Market Cap: €64.1m

Cue Biopharma Management

Management criteria checks 2/4

Cue Biopharma's CEO is Dan Passeri, appointed in Aug 2016, has a tenure of 8.25 years. total yearly compensation is $3.02M, comprised of 20.1% salary and 79.9% bonuses, including company stock and options. directly owns 0.21% of the company’s shares, worth €136.16K. The average tenure of the management team and the board of directors is 6.5 years and 6.3 years respectively.

Key information

Dan Passeri

Chief executive officer

US$3.0m

Total compensation

CEO salary percentage20.1%
CEO tenure8.3yrs
CEO ownership0.2%
Management average tenure6.5yrs
Board average tenure6.3yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Dan Passeri's remuneration changed compared to Cue Biopharma's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-US$45m

Jun 30 2024n/an/a

-US$47m

Mar 31 2024n/an/a

-US$50m

Dec 31 2023US$3mUS$605k

-US$51m

Sep 30 2023n/an/a

-US$52m

Jun 30 2023n/an/a

-US$52m

Mar 31 2023n/an/a

-US$52m

Dec 31 2022US$1mUS$748k

-US$53m

Sep 30 2022n/an/a

-US$47m

Jun 30 2022n/an/a

-US$49m

Mar 31 2022n/an/a

-US$46m

Dec 31 2021US$2mUS$531k

-US$44m

Sep 30 2021n/an/a

-US$47m

Jun 30 2021n/an/a

-US$44m

Mar 31 2021n/an/a

-US$44m

Dec 31 2020US$6mUS$501k

-US$45m

Sep 30 2020n/an/a

-US$43m

Jun 30 2020n/an/a

-US$40m

Mar 31 2020n/an/a

-US$38m

Dec 31 2019US$1mUS$395k

-US$37m

Sep 30 2019n/an/a

-US$39m

Jun 30 2019n/an/a

-US$45m

Mar 31 2019n/an/a

-US$43m

Dec 31 2018US$834kUS$345k

-US$39m

Sep 30 2018n/an/a

-US$38m

Jun 30 2018n/an/a

-US$30m

Mar 31 2018n/an/a

-US$27m

Dec 31 2017US$410kUS$325k

-US$23m

Compensation vs Market: Dan's total compensation ($USD3.02M) is above average for companies of similar size in the German market ($USD472.15K).

Compensation vs Earnings: Dan's compensation has increased whilst the company is unprofitable.

CEO

Dan Passeri (63 yo)

8.3yrs

Tenure

US$3,015,480

Compensation

Mr. Daniel R. Passeri, also known as Dan, MSc. J.D. has been the Chief Executive Officer and Director of Cue Biopharma, Inc. since August 2016 and also served as its President since August 2016 until Octob...

Leadership Team

NamePositionTenureCompensationOwnership
Daniel Passeri
CEO & Director8.3yrsUS$3.02m0.21%
€ 136.2k
Kerri-Ann Millar
Chief Financial Officer6.5yrsUS$1.16m0.023%
€ 14.5k
Ronald Seidel
Co-Founderno dataUS$316.63kno data
Rodolfo Chaparro
Co-Founder & Senior Advisorno dataUS$316.63kno data
Steven Almo
Co-Founder and Chairman of Scientific & Clinical Advisory Boardno datano datano data
Colin Sandercock
Senior VP6.9yrsUS$625.51kno data
Matteo Levisetti
Chief Medical Officer3.8yrsno datano data
Lucinda Warren
Chief Business Officerless than a yearno datano data

6.5yrs

Average Tenure

55yo

Average Age

Experienced Management: 1UC's management team is seasoned and experienced (6.5 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Daniel Passeri
CEO & Director8.3yrsUS$3.02m0.21%
€ 136.2k
Steven Almo
Co-Founder and Chairman of Scientific & Clinical Advisory Board9.8yrsno datano data
Frederick Driscoll
Independent Director6.4yrsUS$76.31k0%
€ 0
Frank Morich
Independent Chairman of the Board6.3yrsUS$106.27k0.044%
€ 28.3k
Peter Kiener
Independent Director8.7yrsUS$144.18k0.00056%
€ 358.9
Hidde L. Ploegh
Member of Scientific & Clinical Advisory Boardno datano datano data
Rafi Ahmed
Member of Scientific Advisory Board1.8yrsno datano data
Kenneth Pienta
Clinical Advisor1.8yrsno datano data
Patrick Verheyen
Independent Director1.6yrsUS$135.31k0.013%
€ 8.3k
Abul K. Abbas
Member of Scientific Advisory Board3.8yrsno datano data
Karolina Palucka
Member of Scientific & Clinical Advisory Board7.8yrsno datano data
Michael Kalos
Member of Scientific Advisory Board3.8yrsno datano data

6.3yrs

Average Tenure

64yo

Average Age

Experienced Board: 1UC's board of directors are considered experienced (6.3 years average tenure).